Investments in the U.S. pharmaceutical manufacturing sector are on the rise, with major players in the industry announcing significant investments in building and expanding facilities across the country. Several factors have contributed to making the U.S. a favorable destination for drug production, including the looming threat of U.S. tariffs and the growing GLP-1 market.
One of the key motivators for pharmaceutical companies to invest in U.S. manufacturing is the potential impact of tariffs on pharmaceutical products. President Donald Trump recently hinted at imposing tariffs as high as 200% on pharma products, prompting companies from around the world to consider increasing their operations in the U.S. to avoid potential financial implications.
In addition to tariff concerns, other industry shifts such as the demand for skilled workers in the tech-heavy manufacturing environment and the growing market for branded drugs have also contributed to the surge in investments in U.S. drug manufacturing.
As a result of this investment boom, billions of dollars are pouring into manufacturing hubs like Raleigh, North Carolina, creating thousands of job opportunities for professionals in various roles including engineers, R&D personnel, and operations professionals.
AstraZeneca, one of the major pharmaceutical companies, recently made its largest-ever single facility investment in the U.S. The company announced a $50 billion investment in manufacturing and R&D in the country, matching similar pledges from other leading pharma companies. The investment includes the construction of a drug substance facility in Virginia and expansions in various other states across the country.
Another pharmaceutical company, Biogen, is also expanding its manufacturing footprint in North Carolina with a $2 billion investment in two campuses in the state’s Research Triangle Park. The investment will focus on expanding capacity for multiple modalities and modernizing operations with automation and AI technology.
Thermo Fisher Scientific, a key player in the pharmaceutical industry, is expanding its production capabilities through a strategic partnership with Sanofi. The company acquired a sterile, fill-finish manufacturing site from Sanofi to strengthen its U.S. manufacturing capabilities for the broader pharma industry.
Overall, the influx of investments in U.S. drug manufacturing is expected to drive growth and innovation in the pharmaceutical sector, creating new opportunities for job seekers and contributing to the country’s position as a global leader in pharmaceutical manufacturing.
